Myelofibrosis: genetic characteristics and the emerging therapeutic landscape
A Tefferi, N Gangat, A Pardanani, JD Crispino - Cancer research, 2022 - AACR
Primary myelofibrosis (PMF) is one of three myeloproliferative neoplasms (MPN) that are
morphologically and molecularly inter-related, the other two being polycythemia vera (PV) …
morphologically and molecularly inter-related, the other two being polycythemia vera (PV) …
[HTML][HTML] Peptides and dendrimers: How to combat viral and bacterial infections
A Falanga, V Del Genio, S Galdiero - Pharmaceutics, 2021 - mdpi.com
The alarming growth of antimicrobial resistance and recent viral pandemic events have
enhanced the need for novel approaches through innovative agents that are mainly able to …
enhanced the need for novel approaches through innovative agents that are mainly able to …
[HTML][HTML] Outcome after transplantation according to reduced-intensity conditioning regimen in patients undergoing transplantation for myelofibrosis
M Robin, R Porcher, C Wolschke… - Biology of Blood and …, 2016 - Elsevier
Allogeneic hematopoietic stem cell transplantation remains the sole curative option for
myelofibrosis. Many transplantation recipients receive a reduced-intensity conditioning (RIC) …
myelofibrosis. Many transplantation recipients receive a reduced-intensity conditioning (RIC) …
Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study
S Kunte, L Rybicki, A Viswabandya, R Tamari… - Leukemia, 2022 - nature.com
We report the results from a multicenter retrospective study of 69 adult patients who
underwent haploidentical blood or marrow transplantation (haplo-BMT) with post …
underwent haploidentical blood or marrow transplantation (haplo-BMT) with post …
[HTML][HTML] Family mismatched allogeneic stem cell transplantation for myelofibrosis: report from the Chronic Malignancies Working Party of European Society for Blood …
K Raj, DJ Eikema, DP McLornan, E Olavarria… - Biology of Blood and …, 2019 - Elsevier
This analysis included 56 myelofibrosis (MF) patients transplanted from family mismatched
donor between 2009 and 2015 enrolled in the European Society for Blood and Marrow …
donor between 2009 and 2015 enrolled in the European Society for Blood and Marrow …
[HTML][HTML] Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute …
Background Thiotepa-busulfan-fludarabine (TBF) is a widely used conditioning regimen in
single umbilical cord blood transplantation (SUCBT). More recently, it was introduced in the …
single umbilical cord blood transplantation (SUCBT). More recently, it was introduced in the …
[HTML][HTML] A modified post-transplant cyclophosphamide regimen, for unmanipulated haploidentical marrow transplantation, in acute myeloid leukemia: a multicenter …
P Chiusolo, G Bug, A Olivieri, M Brune… - Biology of Blood and …, 2018 - Elsevier
We report a modified post-transplant cyclophosphamide (PT-CY) regimen, for
unmanipulated haploidentical marrow transplants, in 150 patients with acute myeloid …
unmanipulated haploidentical marrow transplants, in 150 patients with acute myeloid …
[HTML][HTML] The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review
M Tiribelli, F Palandri, E Sant'Antonio… - Bone Marrow …, 2020 - nature.com
Allogeneic hematopoietic stem-cell transplantation (HSCT) is, at present, the only potentially
curative therapy for myelofibrosis (MF). Despite many improvements, outcomes of HSCT are …
curative therapy for myelofibrosis (MF). Despite many improvements, outcomes of HSCT are …
[HTML][HTML] Haploidentical transplantation with post-transplant cyclophosphamide versus unrelated donor hematopoietic stem cell transplantation: a systematic review …
LJ Arcuri, MTM Aguiar, AAF Ribeiro… - Biology of Blood and …, 2019 - Elsevier
Hematopoietic stem cell transplantation (HSCT) is the standard treatment for patients with
high-risk hematologic malignancies. Only approximately 25% of siblings are HLA-matched …
high-risk hematologic malignancies. Only approximately 25% of siblings are HLA-matched …
[HTML][HTML] Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission
Background A preparatory regimen consisting of thiotepa-busulfan-fludarabine (TBF) has
been associated with reduced relapse in patients with haematological malignancies after …
been associated with reduced relapse in patients with haematological malignancies after …